Multiple Sclerosis Research Repository

“Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis”: Wilson LS et al

-Preventing relapses, the main clinical trial outcome, was not associated with significant preferences (P = .35).

-Patient preference focused on symptoms and prevention of progression but not on relapse prevention, the proven drug outcome. Patients were willing to accept some level of serious risk for certain types and amounts of benefits